Compare FR & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FR | TWST |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.2B |
| IPO Year | 1996 | 2018 |
| Metric | FR | TWST |
|---|---|---|
| Price | $60.78 | $126.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $62.17 | $46.88 |
| AVG Volume (30 Days) | 651.7K | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $727,076,000.00 | $376,572,000.00 |
| Revenue This Year | $11.27 | $18.91 |
| Revenue Next Year | $7.19 | $15.07 |
| P/E Ratio | $36.73 | ★ N/A |
| Revenue Growth | 8.58 | ★ 20.32 |
| 52 Week Low | $50.29 | $23.30 |
| 52 Week High | $69.88 | $155.44 |
| Indicator | FR | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 50.46 |
| Support Level | $60.53 | $115.28 |
| Resistance Level | $60.79 | $155.44 |
| Average True Range (ATR) | 0.88 | 8.91 |
| MACD | -0.10 | -3.36 |
| Stochastic Oscillator | 1.50 | 18.38 |
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. Through its fully integrated operating and investing platform, the company provides facilities and customer service to multinational corporations and regional firms that are essential for their supply chains. The company serves a diverse tenant base across various sectors, including e-commerce, logistics, transportation, manufacturing, retail, consumer services, food and beverage, building materials, wholesale goods, health services, and government.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.